Want to see HSCS full AI Analyst Report?
HSCS Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HSCS Stock 12 Month Forecast
Average Price Target
$12.00
▲(258.21% Upside)
| Highest Price Target$12.00 | Average Price Target$12.00 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Maxim Group
$12
Buy
258.21%
Upside
Reiterated
07/01/26
Ascendiant
$8
Buy
138.81%
Upside
Reiterated
03/23/26
We look forward to further details. HeartSciences is setting up for a large market opportunity: HeartSciences continues to make rapid and systematic progress towards its vision of using the ECG to diagnose heart disease with AI. MyoVista device will complement the current rollout of MyoVista Insights cloud software platform and expected FDA approval of its first diagnostic algorithm likely by 1H2026. With over 100 million ECG tests performed in the US annually, the capability to catch emergent heart pathologies earlier in a patient’s lifespan could save countless lives and many billions of dollars by replacing late-stage interventions with preventative measures. Revenues for HSCS are likely to be substantial. Raising estimates: We are raising our FY26 EPS estimate upward to $(3.28) versus $(3.76) previously on lower expenses.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Maxim Group
$12
Buy
258.21%
Upside
Reiterated
07/01/26
Ascendiant
$8
Buy
138.81%
Upside
Reiterated
03/23/26
We look forward to further details. HeartSciences is setting up for a large market opportunity: HeartSciences continues to make rapid and systematic progress towards its vision of using the ECG to diagnose heart disease with AI. MyoVista device will complement the current rollout of MyoVista Insights cloud software platform and expected FDA approval of its first diagnostic algorithm likely by 1H2026. With over 100 million ECG tests performed in the US annually, the capability to catch emergent heart pathologies earlier in a patient’s lifespan could save countless lives and many billions of dollars by replacing late-stage interventions with preventative measures. Revenues for HSCS are likely to be substantial. Raising estimates: We are raising our FY26 EPS estimate upward to $(3.28) versus $(3.76) previously on lower expenses.
Best Analysts Covering Heart Test Laboratories, Inc.
3 Months
Success Rate
5/11 ratings generated profit
Average Return
-7.75%
Copying Allen Klee's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of -7.75% per trade.
1 Year
Success Rate
5/12 ratings generated profit
Average Return
-37.63%
Copying Lucas Ward's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -37.63% per trade.
2 Years
Success Rate
2/7 ratings generated profit
Average Return
-9.51%
Copying OpenAI Medical - Devices's trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -9.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HSCS Analyst Recommendation Trends
Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
2
2
2
0
1
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
2
2
0
1
Each month's total comprises the sum of three months' worth of ratings.
HSCS Financial Forecast
HSCS Stock Forecast FAQ
What is HSCS’s average 12-month price target, according to analysts?
Based on analyst ratings, Heart Test Laboratories, Inc.’s 12-month average price target is 12.00.
What is HSCS’s upside potential, based on the analysts’ average price target?
Heart Test Laboratories, Inc. has 258.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HSCS a Buy, Sell or Hold?
Heart Test Laboratories, Inc. has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Heart Test Laboratories, Inc.’s price target?
The average price target for Heart Test Laboratories, Inc. is 12.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $12.00. The average price target represents 258.21% Increase from the current price of $3.35.
The highest analyst price target is $12.00 ,the lowest forecast is $12.00. The average price target represents 258.21% Increase from the current price of $3.35.
What do analysts say about Heart Test Laboratories, Inc.?
Heart Test Laboratories, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of HSCS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.